Bioventix PLC

Bioventix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,830.00
  • Today's Change230.00 / 6.39%
  • Shares traded21.58k
  • 1 Year change+16.06%
  • Beta0.3171
Data delayed at least 20 minutes, as of Nov 30 2022 15:12 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

Bioventix PLC (BVXP:LSE) set a new 52-week high during today's trading session when it reached 3,830.00. Over this period, the share price is up 16.06%.
52-week range
2,880.00Mar 07 20223,830.00Nov 30 2022
Markit short selling activity
Previous close3,600.00
Average volume4.24k
Shares outstanding5.21m
Free float4.62m
P/E (TTM)24.67
Market cap187.54m GBP
EPS (TTM)1.46
Annual div (ADY)126.00
Annual div yield (ADY)3.50%
Div ex-dateNov 03 2022
Div pay-dateNov 18 2022
Data delayed at least 20 minutes, as of Nov 30 2022 15:12 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Bioventix PLC shares was Hold at 3,400.00 on 26 Oct 2022Read the full article
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.